학술논문
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Document Type
Academic Journal
Author
Aubrais R; Department of Hematology, Bordeaux University Hospital, Pessac, France.; Bouabdallah K; Department of Hematology, Bordeaux University Hospital, Pessac, France.; Chartier L; Department of Biostatistics, The Lymphoma Academic Research Organization, Pierre-Bénite, France.; Herbaux C; Department of Hematology, Montpellier University Hospital, Montpellier, France.; Banos A; Department of Hematology, Centre Hospitalier de la Cote Basque Bayonne, Bayonne, France.; Brice P; Department of Hematology, Hôpital Saint-Louis, Paris, France.; Sibon D; Department of Hematology, Hôpital Necker-Enfants maladies, Paris, France.; Schiano JM; Department of Hematology, Institut Paoli Calmettes, Marseille, France.; Cluzeau T; Department of Hematology, Nice University Hospital, Nice, France.; Laribi K; Department of Hematology, Centre Hospitalier du Mans, Le-Mans, France.; Le Calloch R; Department of Hematology, Centre Hospitalier de Cornouaille, Quimper, France.; Bellal M; Hematology Institute, University Hospital, Normandy University, Caen, France.; Delapierre B; Hematology Institute, University Hospital, Normandy University, Caen, France.; Daguindau N; Department of Hematology, Centre Hospitalier Annecy Genevois, Annecy, France.; Amorim S; Department of Hematology, Hopital Saint-Vincent, Lille, France.; Agbetiafa K; Department of Hematology, Institut Curie, Paris, France.; Chauchet A; Department of Hematology, Besançon University Hospital, Besançon, France.; Besson C; Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France.; Durot E; Department of Hematology, Reims University Hospital, Reims, France.; Bonnet C; Department of Hematology, Liège University Hospital, Liège, Belgique.; Fouillet L; Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France.; Bijou F; Department of Hematology, Institut Bergonie, Bordeaux, France.; Tournilhac O; Department of Hematology, Estaing University Hospital, Clermont-Ferrand, France.; Gaulard P; Department of Pathology, Henri Mondor Hospital, Université Paris-Est, Créteil, France.; Parrens MC; Department of Pathology, Bordeaux University Hospital, Pessac, France.; Damaj G; Hematology Institute, University Hospital, Normandy University, Caen, France.
Source
Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Subject
Language
English
Abstract
Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients.
(© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
(© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)